Henan Qin
Clinical Key Laboratory Of Integrative Medicine
Dalian, 116000, China
Dalian, 116000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Disproportionality analysis of adverse events associated with tyrosine kinase inhibitors in gastrointestinal stromal tumors in the FDA adverse event reporting system.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: May 11, 2026
The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma.
Journal: Annals of the New York Academy of Sciences
Published: August 04, 2025
Prognostic and Diagnostic Value of Serum Bile Acid Profiles in Pancreatic Cancer: a Retrospective Multicenter Cohort Study.
Journal: Journal of gastrointestinal cancer
Published: July 13, 2025
Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database.
Journal: Expert opinion on drug safety
Published: April 08, 2025
Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy.
Journal: Frontiers in immunology
Published: March 03, 2024
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Journal: Scientific reports
Published: January 08, 2024
Case Report: A long-term survival case of diffuse large B-cell lymphoma with left ventricular infiltration and spinal cord compression.
Journal: Frontiers in cardiovascular medicine
Published: October 08, 2023
Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells.
Journal: Journal of immunology research
Published: January 28, 2023
RIOK3 promotes pancreatic ductal adenocarcinoma cell invasion and metastasis by stabilizing FAK.
Journal: Heliyon
Published: February 09, 2022
Showing 1-12 of 12
Last Updated: 09/26/2026